In:
Arthritis & Rheumatology, Wiley, Vol. 72, No. 1 ( 2020-01), p. 20-30
Abstract:
Systemic lupus erythematosus ( SLE ) patients exhibit accelerated development of atherosclerosis and increased incidents of cardiovascular disease ( CVD ) that cannot be explained by traditional risk factors alone. Accumulating evidence suggests that reduced levels of high‐density lipoproteins ( HDL s), along with altered HDL composition and function, may contribute to the accelerated atherosclerosis in SLE patients. Normally, HDL s play various atheroprotective roles through facilitating cholesterol efflux, inhibiting vascular inflammation, and scavenging oxidative species. However, systemic inflammation, oxidative stress, and autoimmunity in SLE patients induce changes in HDL size distribution and proteomic and lipidomic signatures. These compositional changes in HDL s result in the formation of proinflammatory, dysfunctional HDL . These lupus‐altered HDL s have impaired antiatherogenic function with reduced cholesterol efflux capacities, impaired antioxidation abilities, and diminished antiinflammatory properties. In fact, dysfunctional HDL may promote atherogenesis by inducing inflammation. Thus, dysfunctional HDL s could be an important biomarker of accelerated atherosclerosis in lupus. Additionally, HDL ‐targeted therapies, especially infusion of reconstituted HDL s, may serve as a potential therapeutic intervention for SLE patients with CVD .
Type of Medium:
Online Resource
ISSN:
2326-5191
,
2326-5205
Language:
English
Publisher:
Wiley
Publication Date:
2020
detail.hit.zdb_id:
2754614-7
Permalink